Dr. Trieu, CEO of Oncotelic Therapeutics, was recently a guest on Benzinga's All Access.<br /><br />Oncotelic seeks to improve the outcomes and survival of cancer patients, with a special emphasis on rare pediatric cancers. Its lead asset, OT-101, has a rare pediatric designation for diffuse intrinsic pontine glioma. The company has a host of IPs that are being studied in indications as diverse as leukemia, Parkinson’s Disease and erectile dysfunction.<br /><br />Mr. Trieu spoke about the nanomedicine platform his company is currently building out.
